Risk of Malignancy, Major Adverse Cardiovascular Events, and Liver Injury in Patients with Ulcerative Colitis Treated with Mirikizumab versus Other Biologics: A Secondary Database Study in Japan | HMA-EMA Catalogues of real-world data sources and studies